Cordran SP (flurandrenolide) Cream and Cordran Ointment
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2013
Postmarketing Adverse Reactions
- The following adverse reactions have been identified during post approval use of flurandrenolide, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Skin: skin striae, hypersensitivity, skin atrophy, contact dermatitis and skin discoloration